Dear Editor,

There is no absolutely proven treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The infection continues to spread rapidly worldwide and causes many people deaths. Patients with rheumatic disease can become easily and severely infected with SARS-CoV-2 because their immune system is suppressed [1]. Patients with rheumatic diseases use many immunosuppressants such as disease-modifying antirheumatic drugs. It has been shown in many studies that hydroxychloroquine is effective for SARS-CoV-2 infection [2]. Tocilizumab is used for patients with severe SARS-CoV-2 infection [2]. Steroids use is not recommended during SARS-CoV-2 infection since the drugs may increase the tendency to pneumonia [1].

Cyclosporine is a potent immunosuppressive agent and often uses for immunosuppression after organ transplantation. It is widely used in the treatment of vasculitis by rheumatologists [3]. Cyclosporine can be used in the treatments of Behçet’s disease, psoriatic arthritis, and lupus nephritis [3]. Nowadays, it is not used for the treatment of rheumatoid arthritis [3]. Serious side effects of cyclosporine have limited its use. Administration of immunosuppressive agents inhibits the activation of T cells and render patients with rheumatic diseases susceptible to infections [1]. Therefore, it should be clarified whether cyclosporine can be used in SARS-CoV-2 infection. Cyclosporine is a calcineurin inhibitor that inhibits calcium-dependent interleukin (IL)-2 production. It blocks the calcineurin activity by complexing with cyclophilin in the cell and suppresses gene transcription of IL-2. Cyclosporine has been shown to inhibit SARS-COV viral replication at very low and non-toxic doses [4–6]. Similarly, it inhibits the replication of other coronaviruses and human immune deficiency virus [5, 6]. Cyclosporine can inhibit cyclophilin functions of the SARS-COV virus by inhibiting the peptidyl-prolyl isomerase activity or may act by directly inhibiting the nsp12 RNA-dependent RNA polymerase activity of the virus [6]. There is a resemblance between SARS-CoV-2 and SARS-CoV based on the full-length genome phylogenetic. Therefore, cyclosporine can be successful in SARS-CoV-2 treatment.

It is known that the virus binds to the angiotensin-converting enzyme 2 (ACE2) and enters the cell. The virus binds to ACE2 at low cytosolic pH [7]. The upregulation of ACE2 is thought to increase the viral load and exacerbate the disease [7]. Three important structures maintain cell pH. These ion regulators are lactate/H+ ion symporter (also called monocarboxylate transporters), Na+/H+ exchanger (NHE), and Cl−/HCO3− exchangers. Hydroxychloroquine does not affect any of these channels. It increases intracellular pH through hemi-gap junctional channels [8]. The SARS-CoV-2 infection creates a hypoxic environment by increase lactate. In anaerobic conditions, lactate formation increases by lactate dehydrogenase. MCT pumps lactate and H+ ion simultaneously from the extracellular area to the cytosol to lower the elevated lactate level. NHE becomes active as a reflex due to the increase of H+ ion in the cell [7]. After the activation of NHE, Na+ and Ca+2 are introduced into the cell, while H+ ion is pumped out of the cell. As this reaction continues, the cell continues to swell and lose its functions and eventually dies [7]. It seems that both MCT and NHE are active at the maximum level in SARS-CoV-2 infection.
To break this vicious circle, it is necessary to decrease lactate production and to improve the anaerobic environment. Cyclosporine has been shown to lower the lactate/pyruvate ratio in ischemia–reperfusion injury [9]. The most common NHE isoform in the body is NHE-1. Cyclosporine does not activate NHE-1; it only activates NHE-3 [10]. Therefore, it has no known direct effect on cytosolic pH. Cyclosporine can, thus, prevent cell damage and cell death. Cyclosporin can reduce the viral load by keeping the cytosolic pH at normal values.

Cytokine storm can occur for several reasons. Secondary hemophagocytic lymphohistiocytosis (SHL) is the cause of the cytokine storm in SARS-CoV-2 [11]. Cyclosporine is an appropriate option in the treatment of SHL [12]. Cyclosporine and other calcineurin inhibitors function by blocking key signal pathways downstream of the T-cell antigen receptor. Cyclosporine prevents the production of IL-2, a cytokine necessary for the survival and proliferation of T cells. Inflammation through Nourin stimulates leukocyte chemotaxis, stimulates acute and chronic inflammation, and releases several cytokine storm mediators from monocytes, neutrophils, and endothelial cells [13]. Cyclosporin prevents cytokine storm in H1N1 influenza patients [13].

On the other hand, cyclosporin has undesirable effects. ADAM17 is the metallopeptidase responsible for cleavage of the transmembrane protein tumor necrosis factor-alpha. ADAM17 causes ACE2 cleave [14]. Increasing ACE2 shedding may increment SARS-CoV-2 infection by increasing the ACE2 upregulation [14]. Cyclosporine increases the ADAM17 activity up to threefold [15]. Cyclosporine causes ACE2 upregulation by increasing the ACE2 shedding. Thus, cyclosporin can increase the viral load of SARS-CoV-2.

Cyclosporine has serious side effects such as blood pressure increase, nephrotoxicity, and immune suppression. Its nephrotoxic effect is dose and duration dependent [16]. Cyclosporine can cause hyperlipidemia, gingival hyperplasia, nausea, vomiting, abdominal pain, headache, susceptibility to infections, and triggering of cancer development [16]. Cyclosporine is not administered together with protease inhibitors such as lopinavir/ritonavir. Patients receiving azithromycin are recommended to reduce the cyclosporine dose [17]. It is not clear whether cyclosporine will alleviate or aggravate the SARS-CoV-2 infection. We think that low-dose cyclosporine can only be used in SARS-CoV-2-induced cytokine storm. However, we do not recommend it in SARS-CoV-2 infection since cyclosporine does not have enough preclinical trials yet. Preclinical studies are needed to show that the use of cyclosporine in SARS-CoV-2 infection is beneficial or harmful. We do not ethically approve the use of a drug with serious side effects, such as cyclosporin, in SARS-CoV-2 without detailed preclinical studies.

Funding None.

Compliance with ethical standards
Conflict of interest All authors reported that they have no conflict of interest to declare.

References

1. Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, Lim DH (2020) Coronavirus disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. Rheumatol Int. https://doi.org/10.1007/s00296-020-04584-7
2. Georgiev T (2020) Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int 40:825–826. https://doi.org/10.1007/s00296-020-04570-z
3. Chighizola CB, Ong VH, Meroni PL (2017) The use of cyclosporina in rheumatology: a 2016 comprehensive review. Clin Rev Allergy Immunol 52:401–423. https://doi.org/10.1007/s12016-016-8582-3
4. Carbajo-Lozoya J, Ma-Lauer Y, Malešević M et al (2014) Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res 184:44–53. https://doi.org/10.1016/j.virusres.2014.02.010
5. Russell B, Moss C, George G, Santosalla A et al (2020) Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience 14:1022. https://doi.org/10.3332/ecancer.2020.1022
6. de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y et al (2011) Cycloporin A inhibits the replication of diverse coronaviruses. J Gen Virol 92:2542–2548. https://doi.org/10.1099/vir.0.034983-0
7. Cure E, Cumhur Cure M (2020) Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr 14:405–406. https://doi.org/10.1016/j.dsx.2020.04.024
8. Dixon DB, Takahashi K, Bieda M, Copenhagen DR (1996) Quinine, intracellular pH and modulation of hemi-gap junctions in catfish horizontal cells. Vis Res 36:3925–3931
9. Forssé A, Nielsen TH, Nygaard KH, Nordström CH, Gramsberg JB, Poulsen FR (2019) Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia. Sci Rep 9:3702. https://doi.org/10.1038/s41598-019-40245-x
10. Epting T, Hartmann K, Sandqvist A, Nitschke R, Gordjani N (2020) Cyclosporin A inhibits the replication of SARS-CoV-2. Virus Res 276:108152. https://doi.org/10.1016/j.virusres.2020.108152
11. Behrens EM, Koretzky GA (2017) Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol 69:1135–1143. https://doi.org/10.1002/art.40071
12. Elgebaly SA, Elbayoumi T, Kreutzer DL (2017) Cyclosporin H: a novel anti-inflammatory therapy for influenza H1N1 patients. J Egypt Soc Parasitol 47:25–33
13. Palau V, Riera M, Soler MJ (2020) ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa093
15. Akool ES, Gauer S, Osman B et al (2012) Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling. Biochem Pharmacol 83:286–295. https://doi.org/10.1016/j.bcp.2011.11.001

16. Campana C, Regazzi MB, Buggia I, Molinaro M (1996) Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 30:141–179

17. Perico L, Benigni A, Remuzzi G (2020) Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. https://doi.org/10.1159/000507305

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.